SLC5A2 and chronic kidney disease: The CREDENCE trial in people with CKD and T2D [33] and DAPA-CKD trial in people with CKD with and without T2D [34] were designed to investigate renal outcomes and demonstrated that SGLT2 inhibitors can reduce the risk of worsening CKD.